




PHARMACEUTICAL 2023

Marker Therapeutics Inc.
Rank 284 of 446





PHARMACEUTICAL 2023

Marker Therapeutics Inc.
Rank 284 of 446

The relative strengths and weaknesses of Marker Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Marker Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Marker Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 15%, being 28% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,619
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,782
Liabilities, Non-Current	7,039
Other Assets	17,803
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	15
Other Revenues	9,014
Property and Equipment	0
Research and Development	26,139
Selling, General and Administrative Expense	12,820

Output Variable	Value in 1000 USD
Assets	34,422
Liabilities	14,821
Expenses	38,959
Revenues	9,014
Stockholders Equity	19,601
Net Income	-29,931
Comprehensive Net Income	-29,931
Economic Capital Ratio	15%